Novo Nordisk and Roche Diabetes Care are joining forces to make insulin pump therapy simpler for people with diabetes
Bagsvćrd, Denmark, 22 November 2013 – Today, the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted positive opinion recommending marketing of NovoRapid® (insulin aspart) PumpCart® in Europe. Insulin aspart PumpCart® is a 1.6 ml prefilled insulin pump cartridge containing the rapid-acting insulin aspart. It is compatible with Roche Diabetes Care’s next-generation Accu-Chek® Insight diabetes therapy system.
Insulin aspart PumpCart® has been developed in a non-exclusive partnership between Roche Diabetes Care, a pioneer and global market leader in the development of diabetes management solutions and services, and Novo Nordisk, a world leader in diabetes care. The prefilled cartridge and insulin delivery system is expected to make insulin pump therapy more convenient for people with diabetes.
“Today, insulin pump users go through a rather complicated process of filling disposable plastic reservoirs with insulin, typically from a larger insulin vial. Now, insulin pump users can simply place a prefilled insulin cartridge into their insulin pump without any extra handling steps. Novo Nordisk is committed to continuously improving diabetes care and to make the lives of people with diabetes easier, so we are pleased to provide pump users with this new treatment option”, says Jakob Riis, Executive Vice President, Marketing and Medical Affairs, Novo Nordisk.
Luc Vierstraete, Global Head of Roche Diabetes Care, says "We are excited to be able to offer this solution to our customers and bring to market our innovative Accu-Chek® Insight diabetes therapy system compatible with the option of using the new prefilled insulin cartridge. This can help improve a targeted and effective insulin pump therapy while contributing to a simplified diabetes management in everyday life." (1-5)
Insulin aspart PumpCart® is expected to be launched in selected European countries during 2014/2015.
About Insulin Pump Therapy
An insulin pump delivers insulin from a reservoir inside the pump to a patient's body using an infusion set and a tiny cannula. Insulin pumps use fast-acting insulin such as NovoRapid®. The insulin is delivered using continuous infusion and is often used by people with type 1 diabetes who receive intensified insulin therapy and test their blood glucose levels on a regular basis. An insulin pump provides these patients with more flexibility and is expected to improve glycaemic control and quality of life (6-7). In some countries 15%, and under 5% in other countries, of people in Europe with type 1 diabetes use a pump, in the US 40% are treated with insulin from a pump (8).
About Insulin aspart
Insulin aspart [rDNA origin] injection is a mealtime insulin indicated for the treatment of diabetes mellitus in adults and children aged 2 years and above.
About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately 37,000 employees in 75 countries, and markets its products in more than 180 countries. For more information, visit novonordisk.co.uk.
About Roche Diabetes Care
Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For more than 35 years, the Accu-Chek brand has been dedicated to enable people with diabetes to live life as normal and active as possible as well as to empower healthcare professionals manage their patients’ condition in an optimal way. Today, the Accu-Chek portfolio offers people with diabetes and healthcare professionals innovative products and impactful solutions for convenient, efficient and effective diabetes management. It encompasses blood glucose meters, insulin delivery systems, lancing devices, data management systems and education programs – contributing to an improved medical outcome.
Further information Novo Nordisk
Katrine Sperling, +45 4442 6718, email@example.com
Kasper Roseeuw Poulsen, +45 4442 4303, firstname.lastname@example.org
Frank Daniel Mersebach, +45 4442 0604, email@example.com
Daniel Bohsen, +45 3079 6376, firstname.lastname@example.org
Lars Borup Jacobsen, +45 3075 3479, email@example.com
Jannick Lindegaard (US), +1 609 786 4575, firstname.lastname@example.org
Further information Roche Diabetes Care
Ute Volkmann, +49 621 759 9561, email@example.com
All trademarks used or mentioned in this release are legally protected
1. Pickup, JC, Sutton AJ, Diabetic Medicine. 2008; 25(7):765-774
2. Jeitler, K et al., Diabetologia. 2008; 51(6): 941-951
3. Garg, SK et al., Diabetes Technology and Therapeutics. 2008; 10(5): 369-375
4. Reichel, A et al., Journal of Diabetes Science and Technology. 2013; 7(1): 156-162
5. Ziegler, R et al., Diabetes Care. 2013;36(11):3613-3619
6. Neale D. Cohen, Eui S. Hong, Christy Van Drie, Beverley Balkau, and Jonathan Shaw, ‘Long-Term Metabolic Effects of Continuous Subcutaneous Insulin Infusion Therapy in Type 1 Diabetes’, Diabetes Technology & Therapeutics, Volume 15, Number 7, 2013
7. John C. Pickup Nat. Rev., ‘Management of diabetes mellitus: is the pump mightier than the pen? Endocrinol. 8, 425–433 (2012)
8. Pickup J. Insulin pumps. Int J Clin Pract Suppl. 2011; 170: 16.